The United Laboratories International Holdings (HK:3933) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
The United Laboratories International Holdings Limited has announced the acceptance of their Insulin Degludec Injection by China National Medical Products Administration, marking a significant stride in diabetes treatment with their new generation long-acting basal insulin analog. The company is further developing a range of diabetes-related products, emphasizing its commitment to innovation and value creation in the biopharmaceutical industry for its shareholders.
For further insights into HK:3933 stock, check out TipRanks’ Stock Analysis page.
